Abstract
This chapter discusses the biology of low-dose hyper-radiosensitivity (HRS) with reference to radiation-induced DNA damage and cellular repair processes. Particular attention is paid to the significance of G2-phase cell cycle check-points in overcoming low-dose hyper-radiosensitivity and the impact of HRS on low-dose rate radiobiology. The history of HRS from the original in vivo discovery to the most recent in vitro and clinical data are examined to present a unifying hypothesis concerning the molecular control and regulation of this important low-dose radiation response. Finally, pre-clinical and clinical data are discussed, from a molecular viewpoint, to provide theoretical approaches to exploit HRS biology for clinical gain.
| Original language | English (US) |
|---|---|
| Title of host publication | Targeted Radionuclide Tumor Therapy |
| Subtitle of host publication | Biological Aspects |
| Publisher | Springer Netherlands |
| Pages | 329-347 |
| Number of pages | 19 |
| ISBN (Print) | 9781402086953 |
| DOIs | |
| State | Published - Dec 1 2008 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Low dose hyper-radiosensitivity : A historical perspective. / Marples, Brian; Krueger, Sarah A.; Collis, Spencer J.; Joiner, Michael C.
Targeted Radionuclide Tumor Therapy: Biological Aspects. Springer Netherlands, 2008. p. 329-347.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Low dose hyper-radiosensitivity
T2 - A historical perspective
AU - Marples, Brian
AU - Krueger, Sarah A.
AU - Collis, Spencer J.
AU - Joiner, Michael C.
PY - 2008/12/1
Y1 - 2008/12/1
N2 - This chapter discusses the biology of low-dose hyper-radiosensitivity (HRS) with reference to radiation-induced DNA damage and cellular repair processes. Particular attention is paid to the significance of G2-phase cell cycle check-points in overcoming low-dose hyper-radiosensitivity and the impact of HRS on low-dose rate radiobiology. The history of HRS from the original in vivo discovery to the most recent in vitro and clinical data are examined to present a unifying hypothesis concerning the molecular control and regulation of this important low-dose radiation response. Finally, pre-clinical and clinical data are discussed, from a molecular viewpoint, to provide theoretical approaches to exploit HRS biology for clinical gain.
AB - This chapter discusses the biology of low-dose hyper-radiosensitivity (HRS) with reference to radiation-induced DNA damage and cellular repair processes. Particular attention is paid to the significance of G2-phase cell cycle check-points in overcoming low-dose hyper-radiosensitivity and the impact of HRS on low-dose rate radiobiology. The history of HRS from the original in vivo discovery to the most recent in vitro and clinical data are examined to present a unifying hypothesis concerning the molecular control and regulation of this important low-dose radiation response. Finally, pre-clinical and clinical data are discussed, from a molecular viewpoint, to provide theoretical approaches to exploit HRS biology for clinical gain.
UR - http://www.scopus.com/inward/record.url?scp=84892122569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892122569&partnerID=8YFLogxK
U2 - 10.1007/978-1-4020-8696-0_19
DO - 10.1007/978-1-4020-8696-0_19
M3 - Chapter
SN - 9781402086953
SP - 329
EP - 347
BT - Targeted Radionuclide Tumor Therapy
PB - Springer Netherlands
ER -